Category: by country

“Sufficiently serious” issues in study prompt company to yank drug approval application in China

The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”

Researchers for the company, Reckitt Benckiser, maker of Gaviscon, had published a report on the study in 2015 in the journal Alimentary Pharmacology & Therapeutics. But the journal has now retracted the article, “Randomised clinical trial: The clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China,” at the behest of the drug maker.

According to the notice: Continue reading “Sufficiently serious” issues in study prompt company to yank drug approval application in China

Harvard and the Brigham recommend 31 retractions for cardiac stem cell work

Piero Anversa

Retraction Watch readers may be familiar with the name Piero Anversa. Until several years ago, Anversa, a scientist at Harvard Medical School and the Brigham and Women’s Hospital, was a powerful figure in cardiac stem cell research.

“For ten years, he ran everything,” says Jeffery Molkentin, a researcher at Cincinnati Children’s whose lab was among the first to question the basis of Anversa’s results in a 2014 paper in Nature. Continue reading Harvard and the Brigham recommend 31 retractions for cardiac stem cell work

Chief scientific officer of a high-flying cannabis product company faked data at the NIH

The chief scientific officer of a cannabis product company whose stock price has been hotter than a flaming joint (sorry) was known more than 18 months ago to have committed research misconduct while at the U.S. National Institutes of Health — casting a cloud of suspicion over the firm’s operations.

Marketwatch reported yesterday that the company, India Globalization Capital, which trades on the New York Stock Exchange as IGC, has at least nine other “red flags” for investors, from questions about its ability to manufacture cannabinoids to a history of trouble with the U.S. Securities and Exchange Commission.

Until August, the company’s stock had been trading below 50 cents per share. It began a dramatic rise, eventually reaching $13 per share. MarketWatch notes:

Continue reading Chief scientific officer of a high-flying cannabis product company faked data at the NIH

Dr. What? From the mixed-up files of Muftah Salem Eljamel

Muftah Salem Eljamel

A surgeon in Scotland who mistook a tear duct for a brain tumor, operated on the wrong disc in another patient and eventually gave up his right to practice medicine in the UK has corrected a 2008 paper.

The reason: More confusion, it seems. Muftah Salem Eljamel says he mistook an image in the article as being from his hospital when it belonged to another surgeon at a hospital in Cardiff, some 460 miles distant. And oh, the image wasn’t what he thought it was to begin with.  The Courier reported on the correction.

According to the notice, in the Journal of Neurosurgery: Continue reading Dr. What? From the mixed-up files of Muftah Salem Eljamel

Researchers replicated a classic paper on unsuccessful treatment of writer’s block. Then they tried to write it up.

Matt Brodhead

In 1974, Dennis Upper published a paper — well, to be precise, a blank page — entitled “THE UNSUCCESSFUL SELF-TREATMENT OF A CASE OF “WRITER’S BLOCK.” There have been several attempts to replicate the work, which has become a classic among a certain cohort of academics.

Until late last month, however, there was no multidisciplinary attempt to replicate the study. (As best we can tell, anyway. Who has time to do a proper literature review these days?) Now there is, along with an editor’s note that calls it “an exceptionally fine piece of scholarship.” We felt the best way to celebrate this auspicious occasion — coming about as far on the calendar from April 1 as one can — would be to interview the corresponding author of the new paper, Matt Brodhead, of Michigan State University. Lucky for us, he did not suffer from writer’s block, so he could respond to our questions by email.

Q: We can’t find the actual paper, even though the editor’s note refers to “the article below.” Did you bury your results in the supplemental information?
Continue reading Researchers replicated a classic paper on unsuccessful treatment of writer’s block. Then they tried to write it up.

“Irreconcilable” differences about author order, other issues topple two articles in Spandidos journal

Researchers in China have retracted a pair of papers in the same journal after running into “irreconcilable” differences with the articles.

Both articles appeared in Molecular Medicine Reports, from Spandidos.

One article, “Combined treatment with extracorporeal shock‑wave therapy and bone marrow mesenchymal stem cell transplantation improves bone repair in a rabbit model of bone nonunion,” published in November 2017, suffered from, well, serious nonunion: Continue reading “Irreconcilable” differences about author order, other issues topple two articles in Spandidos journal

Persistence pays off for plagiarized author: emails spur retraction, sanctions against researcher

Note: This post has been updated.

Here’s an object lesson for scientists who find out they’ve been ripped off by other researchers: Taking matters into your own hands can produce results.  

An aggrieved author’s doggedness led to the retraction of a 2013 paper that plagiarized his work, along with the revocation of a doctoral degree by one of the scientists responsible for the theft and sanctions against another.

We don’t often get the blow-by-blow, but in this case we have the details to share. The story begins in early 2017, when Andrew Boyle, a professor of cardiac medicine at the University of Newcastle, in Australia, noticed something fishy in an article, “Cathepsin B inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway.” The paper had appeared in a journal called Molecular Medicine Reports, from Spandidos.

The article, published by a group from Shandong Provincial Hospital, contained a pair of figures that Boyle recognized from his 2005 article in the Journal of Molecular and Cellular Cardiology. One of the images had been altered, but the other was a patent duplication.

Boyle explained that: Continue reading Persistence pays off for plagiarized author: emails spur retraction, sanctions against researcher

Japanese university revokes PhD following a retraction

Tokyo Women’s Medical University has stripped a researcher of her PhD, following the retraction of a paper — for data duplication — that was based on her thesis.

The August 30th announcement notes that a degree was revoked on July 20. The announcement does not name the researcher, but refers to degree number 2881, which corresponds to Rika Nakayama’s PhD. The university describes carelessness and errors, but not misconduct.

Here’s a rough Google translation of the announcement: Continue reading Japanese university revokes PhD following a retraction

A study of an “abortion reversal” method has been republished — but its mystery deepens

A study that claimed a highly controversial “abortion reversal” method was effective — and which was temporarily removed from a journal’s site — has been republished.

While there are some wording changes in the new version, they don’t seem to clarify much about what happened before and during the study. Continue reading A study of an “abortion reversal” method has been republished — but its mystery deepens

Publisher retracts two papers, will correct five more for lab with high “level of disorganization”

A lab at the University of Malaya has lost two papers and will have to correct five more — just from one publisher — over poor lab practices.

One of the retracted papers paper tested the effects of a plant on liver damage; its notice says the paper contains overlap with another paper from the same lab that tested a different plant for the same effect — but to save time and cut costs, the authors tested both plants in animals at the same time, and collected their tissues using one kit and protocol.

The publisher (Hindawi) decided to take a second look at the work coming out of the lab of Mahmood Ameen Abdulla after people raised questions about some of his previous work, including a Scientific Reports paper that was corrected for mistaken duplications, according to Matt Hodgkinson, the head of research integrity at Hindawi. After Hindawi spotted problems, it contacted the institution, which investigated.

According to Hodgkinson, the UM investigation concluded the problems were due to errors, not deliberate misconduct. Hindawi plans to correct five more papers from Abdulla’s lab, after consulting with Hindawi’s board members following UM’s investigation:

Continue reading Publisher retracts two papers, will correct five more for lab with high “level of disorganization”